Epidermolysis Bullosa: Competitive Landscape

Epidermolysis Bullosa: Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Epidermolysis Bullosa therapeutics.

GlobalData epidemiologists estimate that there will be 21,154 diagnosed prevalent cases of EB in 2024, which is expected to increase to 21,578 diagnosed prevalent cases by 2029.

Currently, there is no cure available globally in the EB market space. Existing approved treatments are primarily supportive.

The EB pipeline holds 47 molecules, with two assets in the pre-registration stage, eight assets in Phase III development, and nine assets in Phase II development.

Over the past decade, 104 clinical trials have been conducted in EB. The highest number of studies were initiated in 2018 with 19 trials, followed by 2017 with 13 trials.

During the past decade, partnerships were the most common deal type in North America and Africa. Acquisitions were dominant in Europe. In the Asia-Pacific region, licensing agreements were dominant, while in South and Central America, partnerships accounted for the only deal.

Scope

GlobalData’s Epidermolysis Bullosa: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Epidermolysis Bullosa market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Epidermolysis Bullosa market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.